EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
-0.35 (-5.28%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.24 - 6.75
52 week 5.77 - 32.85
Open 6.56
Vol / Avg. 1.53M/2.04M
Mkt cap 573.06M
P/E     -
Div/yield     -
EPS -1.68
Shares 96.34M
Beta 0.73
Inst. own 93%
Feb 22, 2016
Q4 2015 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Feb 11, 2016
Exact Sciences Corp at Leerink Partners Global Healthcare Conference - 3:05PM EST - Add to calendar
Jan 14, 2016
Exact Sciences Corp at JPMorgan Healthcare Conference (Q&A)
Jan 14, 2016
Exact Sciences Corp at JPMorgan Healthcare Conference
Jan 11, 2016
Preliminary Q4 2015 Exact Sciences Corp Earnings Release
Nov 19, 2015
Exact Sciences Corp at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 19, 2015
Exact Sciences Corp at Goldman Sachs US Emerging & SMID Cap Growth Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -339.97% -5564.40%
Operating margin -342.54% -5591.71%
EBITD margin - -5385.37%
Return on average assets -53.25% -43.55%
Return on average equity -58.78% -47.16%
Employees 236 -
CDP Score - -


441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non‑invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non‑invasive stool‑based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody‑based fecal immunochemical test (FIT). The Company's Cologuard test is designed to detect pre‑cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre‑cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The company's test also detects blood in stool, utilizing an antibody based FIT test.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
John K. Bakewell Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
William J. Megan Senior Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 66
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
John A. Fallon M.D. Director
Age: 68
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 53
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 64
Bio & Compensation  - Reuters